Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment
By Ben Glickman
Shares of Seres Therapeutics rose early Tuesday after the company said it had received Fast Track Designation from the U.S. Food and Drug Administration for its therapeutic candidate.
The stock was up 15% to $1.79 in pre-market trading. Shares are up 62% in the last month, but have fallen 71% in the last year.
The Cambridge, Mass.-based developer of microbiology therapeutics said SER-155 is a microbiome therapeutic meant to prevent gastrointestinal-associated bacterial infections and reduce cases of severe acute graft-versus-host disease in immunocompromised patients receiving stem-cell transplants.
The company said it is expecting the readout from the second cohort in a Phase 1b trial of the therapeutic in the third quarter.
Seres said fourth-quarter sales of VOWST, another microbiome therapeutic approved by the FDA in April, were about $10.4 million and reflected a gross-to-net reduction of 11%.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 09, 2024 07:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued